R&D FDA’s emerging framework to reduce animal testing: Implicati... Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.